Human Organoids Market worth $1,901 million by 2025

Global Revenue Growth:

The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %. Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

By product, liver segment is expected to have the largest market share during the forecast period

The large share of this segment is attributed to factors such as the significant adoption of new technologies  among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of 3D bioprinting  and the increased number of liver tranplants and diseases.

Download PDF Brochure@

Delelopmental biology is the largest application segment of the human orgnaoids market

Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms.

Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.

Pharmaceuticals & Biotechnology companies accounted for the largest share of the human organoids market, by end users, in 2020

Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements.

Technical and regulatory challenges related to the development of new drug molecules create complexities for pharmaceutical and biotechnology companies in terms of time and cost. However, due to strict regulations, companies often produce technologically superior products with better safety norms.

North America is the largest regional market for Human Organoids

North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers. Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.

Key Market Players:

BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

BioIVT founded in 1981 and is headquartered in New York, US. The company is a leading global provider of biological specimens, including human tissues, cell products, blood, and other biofluids. The company provides a wide range of services, ranging from target and biomarker validation, phenotypic assays to characterize novel therapeutics, and clinical assay development to in vitro hepatic modeling solutions. It is a supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.

Request Sample Pages@

Some of the major end users of the company’s products are research organizations, pharmaceutical and biotechnological companies, medical device companies, and academic research institutes. BioIVT offers its products and services across North America, the Asia Pacific, Europe, and the Middle East & Africa. The company has two distributors in the Asia Pacific region, namely, Veritas Corporation (Japan) and Research Institute for Liver Diseases (Shanghai) Co., Ltd. (China).